Develops diagnostic tests for infectious and autoimmune diseases.
Dec 2024Revenue $61.6M/yrExpenses $82.7M/yr
No trendCash runway ≈ 1.1 years from Dec 2024
Figures by year
When will Trinity Biotech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $61.6M and expenses $82.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $61.6M | $82.7M | −$21.2M |
| Dec 2023 | $56.8M | $83.9M | −$27.0M |
| Dec 2022 | $62.5M | $81.9M | −$19.3M |
| Dec 2021 | $81.1M | $77.2M | $3.94M |
| Dec 2020 | $102M | $102M | $82.0K |
| Dec 2019 | $90.4M | $115M | −$24.1M |
| Dec 2018 | $97.0M | $117M | −$20.2M |
| Dec 2017 | $99.1M | $137M | −$37.7M |
| Dec 2016 | $99.6M | $139M | −$39.8M |
| Dec 2015 | $100M | $86.7M | $13.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.